PL1962895T3 - Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów - Google Patents

Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów

Info

Publication number
PL1962895T3
PL1962895T3 PL06848586T PL06848586T PL1962895T3 PL 1962895 T3 PL1962895 T3 PL 1962895T3 PL 06848586 T PL06848586 T PL 06848586T PL 06848586 T PL06848586 T PL 06848586T PL 1962895 T3 PL1962895 T3 PL 1962895T3
Authority
PL
Poland
Prior art keywords
tumor growth
therapeutic use
inhibiting tumor
vegf inhibitor
dll4 antagonist
Prior art date
Application number
PL06848586T
Other languages
English (en)
Inventor
Irene Noguera
Gavin Thurston
Nicholas Gale
Eric Smith
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38163537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1962895(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PL1962895T3 publication Critical patent/PL1962895T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL06848586T 2005-12-16 2006-12-15 Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów PL1962895T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US75117305P 2005-12-16 2005-12-16
US77127606P 2006-02-08 2006-02-08
US78845606P 2006-03-31 2006-03-31
US83054306P 2006-07-12 2006-07-12
EP06848586.1A EP1962895B2 (en) 2005-12-16 2006-12-15 THERAPEUTIC USE OF A Dll4 ANTAGONIST AND A VEGF INHIBITOR FOR INHIBITING TUMOR GROWTH
PCT/US2006/047848 WO2007070671A2 (en) 2005-12-16 2006-12-15 Therapeutic methods for inhibiting tumor growth with dll4 antagonists

Publications (1)

Publication Number Publication Date
PL1962895T3 true PL1962895T3 (pl) 2013-06-28

Family

ID=38163537

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06848586T PL1962895T3 (pl) 2005-12-16 2006-12-15 Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów

Country Status (12)

Country Link
US (1) US20080107648A1 (pl)
EP (1) EP1962895B2 (pl)
JP (1) JP5489465B2 (pl)
AU (1) AU2006326417B2 (pl)
CA (1) CA2630839C (pl)
DK (1) DK1962895T3 (pl)
ES (1) ES2400666T5 (pl)
IL (1) IL191810A (pl)
NZ (1) NZ568739A (pl)
PL (1) PL1962895T3 (pl)
PT (1) PT1962895E (pl)
WO (1) WO2007070671A2 (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
AU2007319672B2 (en) * 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
CA2654304A1 (en) * 2006-06-06 2007-12-13 Genentech, Inc. Compositions and methods for modulating vascular development
ES2557953T3 (es) * 2006-09-29 2016-01-29 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para diagnosticar y tratar cáncer
BRPI0715989A8 (pt) * 2006-10-19 2018-03-13 Genentech Inc "seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmentos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição"
CA2666179A1 (en) 2006-10-19 2008-11-13 Genentech, Inc. Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
AR064388A1 (es) * 2006-12-18 2009-04-01 Genentech Inc Anticuerpos antagonistas anti- notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3
EP2120996A2 (en) * 2006-12-20 2009-11-25 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
US8148147B2 (en) 2007-01-24 2012-04-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008091222A1 (en) * 2007-01-26 2008-07-31 Bioinvent International Ab Dll4 signaling inhibitors and uses thereof
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
EP2899211A1 (en) 2008-07-08 2015-07-29 OncoMed Pharmaceuticals, Inc. Notch1 receptor binding agents and methods of use thereof
US7544476B1 (en) * 2008-07-11 2009-06-09 Aveo Pharmaceuticals, Inc. Identifying cancers sensitive to treatment with inhibitors of notch signaling
KR20110057244A (ko) 2008-09-19 2011-05-31 메디뮨 엘엘씨 Ｄｌｌ4에 대한 항체 및 이의 용도
WO2010039832A1 (en) * 2008-10-01 2010-04-08 Genentech, Inc. Anti-notch2 antibodies and methods of use
JP2012508017A (ja) 2008-11-07 2012-04-05 ファブラス エルエルシー 抗ｄｌｌ４抗体及びその使用
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
CN102741288B (zh) 2009-08-29 2015-08-19 Abbvie公司 治疗用dll4结合蛋白
US20110195494A1 (en) 2009-10-02 2011-08-11 Boehringer Ingelheim International Gmbh Dll4-binging molecules
US20110172398A1 (en) 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
TR201818814T4 (tr) 2009-10-16 2019-01-21 Oncomed Pharm Inc Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı.
JP2013512278A (ja) * 2009-12-01 2013-04-11 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｋ−ｒａｓ変異を含んだ癌を処置するための方法
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
EP2523682B1 (en) 2010-01-13 2015-12-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
AU2011223919B2 (en) 2010-03-02 2015-03-19 Abbvie Inc. Therapeutic DLL4 binding proteins
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
EP3485903B1 (en) 2011-09-23 2022-11-16 Mereo BioPharma 5, Inc. Vegf/dll4 binding agents and uses thereof
US20140093498A1 (en) 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
JP6371294B2 (ja) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
CA2966042A1 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CN109071644B (zh) 2015-09-23 2023-09-19 昂考梅德药品有限公司 治疗癌症的方法和组合物
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂
WO2023063842A1 (ru) * 2021-10-12 2023-04-20 Общество с ограниченной ответственностью "Пальмира Биофарма" Нуклеотидная последовательность, кодирующая слитый белок
WO2024130165A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121045A (en) * 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
WO1998045331A2 (en) † 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
ES2284205T3 (es) * 1997-05-14 2007-11-01 Asahi Kasei Kabushiki Kaisha Nuevo inhibidor de diferenciacion.
EP1179541B1 (en) † 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ATE417928T1 (de) † 1999-06-08 2009-01-15 Regeneron Pharma Vegf-rezeptorchimären zur behandlung von augenkrankheiten, welche durch vaskuläre permeabilität charakterisiert sind.
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
AU2002339157A1 (en) * 2001-11-14 2003-05-26 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
CA2469204A1 (en) * 2001-12-07 2003-06-19 Regents Of The University Of Michigan Prospective identification and characterization of breast cancer stem cells
WO2004024764A1 (en) 2002-09-10 2004-03-25 Lorantis Limited Pharmaceutical composition and medical treatments comprising notch ligand proteins
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
CA2621226A1 (en) 2005-09-01 2007-03-08 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
CA2654304A1 (en) * 2006-06-06 2007-12-13 Genentech, Inc. Compositions and methods for modulating vascular development
AU2007319672B2 (en) † 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same

Also Published As

Publication number Publication date
IL191810A0 (en) 2009-02-11
US20080107648A1 (en) 2008-05-08
ES2400666T3 (es) 2013-04-11
EP1962895A2 (en) 2008-09-03
CA2630839A1 (en) 2007-06-21
CA2630839C (en) 2017-01-17
JP2009519944A (ja) 2009-05-21
WO2007070671A3 (en) 2008-01-10
EP1962895B2 (en) 2016-01-20
EP1962895B1 (en) 2013-02-13
AU2006326417B2 (en) 2012-05-24
IL191810A (en) 2017-11-30
ES2400666T5 (es) 2016-03-10
JP5489465B2 (ja) 2014-05-14
WO2007070671A2 (en) 2007-06-21
PT1962895E (pt) 2013-03-28
NZ568739A (en) 2010-09-30
AU2006326417A1 (en) 2007-06-21
DK1962895T3 (da) 2013-03-04

Similar Documents

Publication Publication Date Title
PT1962895E (pt) Utilização terapêutica de um antagonista dll4 e de um inibidor fcev para inibição de crescimento de tumores
EP1753428A4 (en) INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
HK1139036A1 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
IL179514A0 (en) Method of administering and using vegf inhibitors for the treatment of malignant pleural effusion
ZA200704796B (en) Selecting patients for therapy with a HER inhibitor
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
EP2063897A4 (en) KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP2063896A4 (en) KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
IL201650A0 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
EP2143443A4 (en) COMBINED USE OF A DIPEPTIDYL PEPTIDASE IV INHIBITOR COMPOUND AND A SWEETENER
GB0625659D0 (en) Therapeutic compounds and their use
HK1112895A1 (en) 5-heteroaryl thiazoles and their use as pi3k inhibitors
EP1812432A4 (en) COMBINATION OF AN SRC KINASE INHIBITOR AND A BCR ABL INHIBITOR FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP1827391A4 (en) DOSAGE FORMS AND METHODS OF USE THEREOF
ZA200610772B (en) Quinazolinone derivatives as PARP inhibitors
PL1999136T3 (pl) Peptydomimetyczne inhibitory PSMA, związki je zawierające i sposoby ich zastosowania
EP2046122A4 (en) HEMOXYGENASE INHIBITORS AND METHOD FOR THEIR THERAPEUTIC APPLICATION
HK1133597A1 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
EP1789027A4 (en) Therapeutic Use of Anti- TF Antigen Antibodies
ZA200710218B (en) Mitotic kinesin inhibitors and methods of use thereof
HK1170908A1 (en) Novel compounds and therapeutic use thereof for protein kinase inhibition
IL206891A0 (en) Therapeutic inhibitors of pai-1 function and methods of their use
EP1951286A4 (en) COMBINED USE OF INHIBITORS OF DPP-IV AND GASTRIN COMPOUNDS
GB0422439D0 (en) Inhibitors of infection
SI1962895T1 (sl) Terapevtska uporaba DII4 antagonista in VEGF inhibitorja za inhibiranje tumorske rasti